Beliefs and attitudes about bupropion: Implications for medication adherence and smoking cessation treatment.

Fucito, Lisa M.; Toll, Benjamín A.; Salovey, Peter; O’Malley, Stephanie S.

doi:10.1037/a0015695

Cited by 35 publications

(34 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To measure beliefs and attitudes (motivation), we adapted Fucito's 6-item beliefs and attitudes about bupropion measure (Crobach's α = .86) which uses a 5-point likert scale. 8 The 8-item varenicline information scale was adapted from the Life Windows IMB Adherence Assessment Questionnaire (Crobach's α = .65) and was assessed on a 5-point likert scale (1 = strongly disagree, 5 = strongly agree). 30 Varenicline adherence self-efficacy (behavioral skills) was assessed with a 17-item survey using 4-point likert scale (1 = not at all sure, 4 = extremely sure), with 12 items adapted from the Medication Adherence Self-Efficacy Scale and 5 items from the Adherence Self-Efficacy Scale (Crobach's α = .92).…”

Section: Baseline Measuresmentioning

confidence: 99%

See 1 more Smart Citation

Correlates of Adherence to Varenicline Among HIV+ Smokers

Shelley

Tseng

Gonzalez

et al. 2015

NICTOB

View full text Add to dashboard Cite

Introduction: Low rates of adherence to smoking cessation pharmacotherapy may limit the effectiveness of treatment. However, few studies have examined adherence in smoking cessation trials thus, there is a limited understanding of factors that influence adherence behaviors. This brief report analyzes correlates of adherence to varenicline among people living with HIV/AIDS. Methods: Study participants were recruited from three HIV care centers in New York City and enrolled in a three-arm randomized controlled pilot study in which all subjects received varenicline. At the 1-month study visit, there were no significant differences in adherence by study condition, therefore we combined treatment arms to examine correlates of adherence (n = 127). We used pill counts to assess varenicline adherence, defined as taking at least 80% of the prescribed dose. We conducted a multivariate path analysis to assess factors proposed by the informationmotivation-behavioral skills model to predict adherence. Results: Only 56% of smokers were at least 80% adherent to varenicline at 1 month. Adherencerelated information, self-efficacy, a college degree, and non-Hispanic white race/ethnicity were associated with increased varenicline adherence. In path analysis, information and motivation were associated with increased adherence self-efficacy, and adherence self-efficacy was associated with increased adherence, but with marginal significance. These associations with adherence were no longer significant after controlling for race/ethnicity and education. Conclusions: Further exploration of the role of a modifiable correlates of adherence, such as adherencerelated information, motivation and self-efficacy is warranted. Interventions are needed that can address disparities in these and other psychosocial factors that may mediate poor medication adherence.

show abstract

Section: Baseline Measuresmentioning

confidence: 99%

“…[3][4][5][6][7] However, similar to findings in the general population, treatment adherence among HIV+ smokers is poor and declines over time. [8][9][10] Despite the overwhelming burden of tobacco-related…”

Section: Introductionmentioning

confidence: 99%

Correlates of Adherence to Varenicline Among HIV+ Smokers

Shelley

Tseng

Gonzalez

et al. 2015

NICTOB

View full text Add to dashboard Cite

show abstract

“…These studies have shown that smokers often display negative attitudes towards pharmacologically assisted cessation and express concern about their safety and efficacy (Ferguson et al, 2011;Gross et al, 2008;Mooney et al, 2006). Not surprisingly, these negative perceptions predict a lower intention to use pharmacotherapies and poorer adherence in those smokers who do use them Etter & Perneger, 2001;Fucito et al, 2009;Shiffman et al, 2008).…”

Section: Chapter 6 Why Don't Smokers Want Help To Quit? a Qualitativmentioning

confidence: 99%

“…The listing of varenicline on the PBS in 2008 increased use from 5% to 24% between 2007 and 2008 (Cooper et al, 2011). Despite high use of pharmacotherapies, there is evidence of poor adherence, with many users prematurely discontinuing use (Balmford, Borland, Hammond, & Cummings, 2011;Fucito, Toll, Salovey, & O'Malley, 2009;Shelley et al, 2015). Also, despite previous studies showing NRT purchased over the counter is as effective as NRT bought on prescription (Hughes, Shiffman, Callas, & Zhang, 2003), more recent evidence suggests that NRT purchased over the counter may not increase quitting (Hughes, Peters, & Naud, 2011).…”

Section: Pharmacotherapy For Smoking Cessation and The Role Of The Hementioning

confidence: 99%

See 1 more Smart Citation

The biomedicalisation of smoking cessation: a mixed methods study of lay perspectives on nicotine addiction

Morphett¹

View full text Add to dashboard Cite

Biomedical models of addiction are becoming increasingly prevalent in public discourse about cigarette smoking, however there is some concern that smoking is becoming overly medicalised. Neuroscience research has revealed that nicotine use is associated with longlasting changes in the brain, and these findings are being presented in the media and in advertising campaigns for smoking cessation pharmacotherapies. The "brain disease model of addiction", which posits that chronic drug use leads to long-term changes in brain networks that make it very difficult to quit, is increasingly being applied to tobacco dependence. This is controversial in the tobacco control field, where population-based strategies have been successful in reducing the prevalence of smoking. Proponents of a biomedical model of tobacco dependence believe that it will lead to increased treatment seeking, more efficacious treatments, and a reduction in stigma. Critics of a biomedical model of nicotine addiction have expressed concerns that it will reduce individual responsibility for smoking, increase stigma, and undermine individuals' beliefs in their ability to quit. While these competing views on the impacts of biomedical models of addiction have been debated in the academic literature, it is unknown to what extent members of the public endorse a biomedical model of tobacco dependence, and have incorporated it into their everyday understandings of smoking.This research examined the influence of biomedical discourses of smoking on lay beliefs of Australian smokers and non-smokers about tobacco dependence and its treatment. It also explored daily smokers' attitudes to the labelling of nicotine addiction as a "brain disease." A mixed methods approach was used to ascertain the extent to which biomedical understandings of smoking have been incorporated into lay discourse on smoking and quitting; how Australian smokers understand nicotine addiction and the role of the brain; and how endorsement of the brain disease model of addiction may be related to smokers' attitudes towards smoking cessation and preferences for quitting methods.The thesis is comprised of three studies. Firstly, a secondary analysis of data from interviews with 55 members of the general public, including never smokers, ex-smokers and current smokers. The data was analysed to ascertain public attitudes on the best methods for quitting smoking. Results revealed that while cessation medications were frequently described as a helpful means to quit, the role of willpower, choice, and motivation were seen as central.iii Medications were often described as a "second line of defence", or as aids to be used alongside counselling or behavioural strategies.A second qualitative study involved in-depth interviews with 29 daily smokers about their views on smoking cessation and their understanding of the role of the brain in smoking. The results revealed positive attitudes to quitting without assistance. Cessation medications were not perceived as magic bullets, and willpower and perso...

show abstract

Association of Patient Belief About Success of Antibiotics for Appendicitis and Outcomes

et al. 2022

View full text Add to dashboard Cite

ImportanceA patient’s belief in the likely success of a treatment may influence outcomes, but this has been understudied in surgical trials.ObjectiveTo examine the association between patients’ baseline beliefs about the likelihood of treatment success with outcomes of antibiotics for appendicitis in the Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) trial.Design, Setting, and ParticipantsThis was a secondary analysis of the CODA randomized clinical trial. Participants from 25 US medical centers were enrolled between May 3, 2016, and February 5, 2020. Included in the analysis were participants with appendicitis who were randomly assigned to receive antibiotics in the CODA trial. After informed consent but before randomization, participants who were assigned to receive antibiotics responded to a baseline survey including a question about how successful they believed antibiotics could be in treating their appendicitis.InterventionsParticipants were categorized based on baseline survey responses into 1 of 3 belief groups: unsuccessful/unsure, intermediate, and completely successful.Main Outcomes and MeasuresThree outcomes were assigned at 30 days: (1) appendectomy, (2) high decisional regret or dissatisfaction with treatment, and (3) persistent signs and symptoms (abdominal pain, tenderness, fever, or chills). Outcomes were compared across groups using adjusted risk differences (aRDs), with propensity score adjustment for sociodemographic and clinical factors.ResultsOf the 776 study participants who were assigned antibiotic treatment in CODA, a total of 425 (mean [SD] age, 38.5 [13.6] years; 277 male [65%]) completed the baseline belief survey before knowing their treatment assignment. Baseline beliefs were as follows: 22% of participants (92 of 415) had an unsuccessful/unsure response, 51% (212 of 415) had an intermediate response, and 27% (111 of 415) had a completely successful response. Compared with the unsuccessful/unsure group, those who believed antibiotics could be completely successful had a 13–percentage point lower risk of appendectomy (aRD, −13.49; 95% CI, −24.57 to −2.40). The aRD between those with intermediate vs unsuccessful/unsure beliefs was −5.68 (95% CI, −16.57 to 5.20). Compared with the unsuccessful/unsure group, those with intermediate beliefs had a lower risk of persistent signs and symptoms (aRD, −15.72; 95% CI, −29.71 to −1.72), with directionally similar results for the completely successful group (aRD, −15.14; 95% CI, −30.56 to 0.28).Conclusions and RelevancePositive patient beliefs about the likely success of antibiotics for appendicitis were associated with a lower risk of appendectomy and with resolution of signs and symptoms by 30 days. Pathways relating beliefs to outcomes and the potential modifiability of beliefs to improve outcomes merit further investigation.Trial RegistrationClinicalTrials.gov Identifier: NCT02800785

show abstract

Beliefs and attitudes about bupropion: Implications for medication adherence and smoking cessation treatment.

Cited by 35 publications

References 64 publications

Correlates of Adherence to Varenicline Among HIV+ Smokers

Correlates of Adherence to Varenicline Among HIV+ Smokers

The biomedicalisation of smoking cessation: a mixed methods study of lay perspectives on nicotine addiction

Association of Patient Belief About Success of Antibiotics for Appendicitis and Outcomes

Contact Info

Product

Resources

About